All authors contributed to the development of this work and
its review and agreed with its content.
REFERENCES
1. The Global Cancer Observatory (GCO) 2020 http://gco.iarc.fr
2. NORDCAN/IARC 2021 https://nordcan.iarc.
3. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients/ [edited by] Mario E Lacouture: Wiley Blackwell, Hoboken New Jersey, USA 2014. ISBN 978-0-470-62188-2.
4. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a crosssectional study. Cancer Res Treat. 2018 Oct;50(4):1186-93.
5. Lacouture ME et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351-7.
6. Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477-482.
7. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with ir cAEs. J Am Acad Dermatol. 2020;82(4):994-996.
8. Barrios DM, Phillips GS, Feites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1340-1347. doi: 10.1111/jdv.16159.
9. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at MSKCC. J Am Acad Dermatol. 2017;76(6):AB45.
10. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter; 2020 S Oct(10):1-12. https:// www.skintherapyletter.com/wp-content/uploads/2020/10/STLdigital- oncology-skincare.pdf
11. Friese CR, Harrison JM, Janz NK et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017 Jun 1;123(11):1925-1934. doi: 10.1002/ cncr.30547. Epub 2017 Jan 24.
12. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian skin management in oncology (CaSMO) algorithm for patients with oncology treatment-related skin toxicities. Skin Ther Letter; 2021 S March (3):1-10. In-print
13. Brouwers M, Kho ME, Browman GP, et al.; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010,182:E839-42
14. Trevelyan EG, Robinson N. (2015). Delphi methodology in health research: how to do it? Eur J Integrative Med. 2015;7(4):423-428.
15. Smith Begolka W, Elston DM, Beutner KR. American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency. J Am Acad Dermatol. 2011 Jun;64(6):e105-12. doi: 10.1016/j. jaad.2010.10.029.
16. Rosenthal A, Irailevich R, Mov R. Management of acute radiation dermatitis: A review of the literature and proposal for a treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-67.
17. Ferreira MN, Ramseier JY, Leventhal S. et al. Dermatologic conditions in women receiving systemic cancer therapy. Int J Women Dermatol. 2019;5(5):285-307. https://doi.org/10.1016/j. ijwd.2019.10.003 (3)
18. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 April 1, 2018. https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm
19. Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncology (Williston Park). 2017 Dec 15;31(12):885-7, 894-9.
20. Schnur JB, Quellette SC, Dilorenzo TA, et al. A quantitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260-8.
21. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724- 728.
22. Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: A clinicoepidemiological study. Indian J Dermatol. Jan-Feb 2018;63(1):41-6.
23. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse cutaneous drug reactions: An updated review on risks associated with anticancer targeted therapy or immunotherapy. J Immunol Res. 2018 Jan 17;2018:5376476
24. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. Am J Clin Dermatol. 2018 Jun;19(3):345-361.
25. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb;44(2):158-76.
26. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016 Apr;43(4):339-46.
27. Voudouri D, Nikolaou V, Laschos K, et al.Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. Nov-Dec 2017;41(6):407-12.
28. Rofe O, Bar-Sela G, Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol. 2017 Apr;42(3):309- 12.
29. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-84.
30. Falk SJ, Bober S. Vaginal health during breast cancer treatment. Curr Oncol Rep. 2016;18(5):32-
31. Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1-7.
32. Yagasaki K, Komatsu H, Hamamoto Y. Targeted therapy-induced facial skin toxicities: Impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172-177.
33. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. evaluation of a comprehensive skin toxicity program for patients treated with EGFRi. 2020 Jul 1. JAMA Dermatol. 2020;e201795.
34. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, et al. Algorithm for dermocosmetic use in the management of cutaneous sideeffects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013, 27, 1071–1080.
2. NORDCAN/IARC 2021 https://nordcan.iarc.
3. Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients/ [edited by] Mario E Lacouture: Wiley Blackwell, Hoboken New Jersey, USA 2014. ISBN 978-0-470-62188-2.
4. Lee J, Lim J, Park JS, et al. The impact of skin problems on the quality of life in patients treated with anticancer agents: a crosssectional study. Cancer Res Treat. 2018 Oct;50(4):1186-93.
5. Lacouture ME et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28(8):1351-7.
6. Aizman L, Nelson K, Sparks AD, Friedman AJ. The influence of supportive oncodermatology interventions on patient quality of life: a cross-sectional survey. J Drugs Dermatol. 2020;19(5):477-482.
7. Chen ST, Molina GE, Lo JA, et al. Dermatology consultation reduces interruption of oncologic management among hospitalized patients with ir cAEs. J Am Acad Dermatol. 2020;82(4):994-996.
8. Barrios DM, Phillips GS, Feites-Martinez A, Hsu M, Ciccolini K, Skripnik Lucas A, Marchetti MA, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1340-1347. doi: 10.1111/jdv.16159.
9. Barrios DCK, Phillips G, Lucas AS, et al. Anticancer therapy interruption and diagnostic concordance between referring clinicians and dermatologists at MSKCC. J Am Acad Dermatol. 2017;76(6):AB45.
10. Sauder MB, Addona M, Andriessen A, et al. The role of skin care in oncology patients. Skin Ther Letter; 2020 S Oct(10):1-12. https:// www.skintherapyletter.com/wp-content/uploads/2020/10/STLdigital- oncology-skincare.pdf
11. Friese CR, Harrison JM, Janz NK et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017 Jun 1;123(11):1925-1934. doi: 10.1002/ cncr.30547. Epub 2017 Jan 24.
12. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian skin management in oncology (CaSMO) algorithm for patients with oncology treatment-related skin toxicities. Skin Ther Letter; 2021 S March (3):1-10. In-print
13. Brouwers M, Kho ME, Browman GP, et al.; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010,182:E839-42
14. Trevelyan EG, Robinson N. (2015). Delphi methodology in health research: how to do it? Eur J Integrative Med. 2015;7(4):423-428.
15. Smith Begolka W, Elston DM, Beutner KR. American Academy of Dermatology evidence-based guideline development process: responding to new challenges and establishing transparency. J Am Acad Dermatol. 2011 Jun;64(6):e105-12. doi: 10.1016/j. jaad.2010.10.029.
16. Rosenthal A, Irailevich R, Mov R. Management of acute radiation dermatitis: A review of the literature and proposal for a treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-67.
17. Ferreira MN, Ramseier JY, Leventhal S. et al. Dermatologic conditions in women receiving systemic cancer therapy. Int J Women Dermatol. 2019;5(5):285-307. https://doi.org/10.1016/j. ijwd.2019.10.003 (3)
18. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 April 1, 2018. https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm
19. Leventhal J, Young MR. Radiation dermatitis: recognition, prevention, and management. Oncology (Williston Park). 2017 Dec 15;31(12):885-7, 894-9.
20. Schnur JB, Quellette SC, Dilorenzo TA, et al. A quantitative analysis of acute skin toxicity among breast cancer radiotherapy patients. Psychooncology. 2011;20(3):260-8.
21. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724- 728.
22. Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: A clinicoepidemiological study. Indian J Dermatol. Jan-Feb 2018;63(1):41-6.
23. Ng CY, Chen CB, Wu MY, et al Anticancer drugs induced severe adverse cutaneous drug reactions: An updated review on risks associated with anticancer targeted therapy or immunotherapy. J Immunol Res. 2018 Jan 17;2018:5376476
24. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. Am J Clin Dermatol. 2018 Jun;19(3):345-361.
25. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb;44(2):158-76.
26. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016 Apr;43(4):339-46.
27. Voudouri D, Nikolaou V, Laschos K, et al.Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. Nov-Dec 2017;41(6):407-12.
28. Rofe O, Bar-Sela G, Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol. 2017 Apr;42(3):309- 12.
29. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-84.
30. Falk SJ, Bober S. Vaginal health during breast cancer treatment. Curr Oncol Rep. 2016;18(5):32-
31. Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1-7.
32. Yagasaki K, Komatsu H, Hamamoto Y. Targeted therapy-induced facial skin toxicities: Impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172-177.
33. Yu Z, Dee EC, Bach DQ, Mostaghimi A, LeBoeuf NR. evaluation of a comprehensive skin toxicity program for patients treated with EGFRi. 2020 Jul 1. JAMA Dermatol. 2020;e201795.
34. Dreno B, Bensadoun RJ, Humbert P, Krutmann J, et al. Algorithm for dermocosmetic use in the management of cutaneous sideeffects associated with targeted therapy in oncology. J Eur Acad Dermatol Venerol. 2013, 27, 1071–1080.
